• Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

    November 22, 2011 Biodesix today announced that results from a prospectively designed, retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). The purpose of the study was to evaluate the ability of the diagnostic test, VeriStrat, to predict patient outcomes ... Read more
  • Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

    November 2, 2011 Biodesix Inc, a fully integrated molecular diagnostic company dedicated to personalizing medicine, announced today the publication of “Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs” by Lazzari, et al. in the November issue of the Journal of Thoracic Oncology, currently available online. The study retrospectively evaluated ... Read more
  • Biodesix to Present at BioConference Live – Innovative Online Conference

    October 24, 2011 ***Media Advisory*** WHAT: BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26-27. Biodesix, based in Broomfield, CO, is a fully integrated molecular diagnostic company developing products for personalized medicine that improve clinical decision ... Read more
  • VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients

    October 18, 2011 Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes. ... Read more
  • Biodesix to Work with Concentra and Hooper Holmes to Expand Access to VeriStrat®

    October 13, 2011 Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing. VeriStrat® is a blood-based test that helps physicians guide ... Read more
  • Biodesix Selected to Present at Multi-State Investor and Partnering Conference

    September 27, 2011 WHAT: The Rocky Mountain Life Science Investor and Partnering Conference (RMLIPC) Selection Committee has chosen Biodesix to present to more than 50 national investors and partnering entities at its 2011 conference September 21-22 in Denver. Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA). ... Read more
  • Biodesix Closes Series D Financing

    July 14, 2011 Biodesix Inc., a fully integrated molecular diagnostic company developing products that improve clinical decision making , has closed on a $20 million Series D financing. The new capital will support ongoing commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for ... Read more
  • Biodesix Supports Unique Lung Cancer Research Initiative – CASTLE study enrolls initial subjects

    May 6, 2011 Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute (ALCMI, pronounced as “Alchemy”). The CASTLE (Collaborative Advanced Stage Tissue Lung Cancer) study is recruiting a minimum of 250 subjects over two years among academic and community ... Read more
  • Biodesix Issued Four Additional U.S. Patents for Blood-based Oncology Tests

    April 12, 2011 Biodesix, Inc., a fully integrated molecular diagnostics company advancing products for personalized medicine, today announced that the U.S. Patent & Trademark Office (PTO) has issued four patents which collectively provide broad intellectual property protection for the Company’s products and technology. The patents provide additional coverage in multiple tumor types ... Read more
  • Biodesix Receives Certification from NY State

    March 1, 2011 Biodesix, Inc., a fully integrated molecular diagnostics company advancing the development of products for personalized medicine, today announced that they have received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center. With this certification, VeriStrat®, a serum proteomic test to ... Read more